secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001193125-26-130480
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest FY2025 net loss $26.3M; cash $7.7M; completed CAR-T acquisition
-----------------------------------------------------------------------

- Net loss improved to $26.3M ($6.33/share) vs $41.8M ($19.50/share) in 2024.
- Cash at $7.7M at Dec 31, 2025, down from $30.3M at Dec 31, 2024.
- Completed all-stock acquisition of CAR-T assets from Factor Bioscience, including clinical-stage TPST-2003.
- TPST-2003 showed 100% CR in 6 evaluable rrMM patients; median PFS 23.1 months in prior IIT.
- Raised $2M upfront in March 2026 private placement with up to $4M additional from warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312526130480/0001193125-26-130480-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312526130480/tpst-20260330.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-130480

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer